Ke Li, Chao Lin, Yu-Han Hu, Jun Wang, Zhen Jin, Zhen-Ling Zeng* and You-Zhi Tang*,
{"title":"含噻唑的 Pleuromutilin 衍生物的设计、合成、生物学评价和分子对接研究","authors":"Ke Li, Chao Lin, Yu-Han Hu, Jun Wang, Zhen Jin, Zhen-Ling Zeng* and You-Zhi Tang*, ","doi":"10.1021/acsinfecdis.3c00718","DOIUrl":null,"url":null,"abstract":"<p >In this study, we designed and synthesized a series of pleuromutilin derivatives containing thiazole. The <i>in vitro</i> antimicrobial efficacy of these synthesized compounds was examined by using four strains. Compared with tiamulin (MIC = 0.25 μg/mL), compound <b>14</b> exhibited potency in inhibiting MRSA growth (MIC = 0.0625 μg/mL) in these derivatives. Meanwhile, the time-killing kinetics further demonstrated that compound <b>14</b> could efficiently inhibit the MRSA growth. After exposure at 4 × MIC, the postantibiotic effect (PAE) of compound <b>14</b> was 1.29 h. Additionally, in thigh-infected mice, compound <b>14</b> exhibited a more potent antibacterial efficacy (−1.78 ± 0.28 log<sub>10</sub> CFU/g) in reducing MRSA load compared to tiamulin (−1.21 ± 0.23 log<sub>10</sub> CFU/g). Moreover, the MTT assay on RAW 264.7 cells demonstrated that compound <b>14</b> (8 μg/mL) had no significant cytotoxicity. Docking studies indicated the strong affinity of compound <b>14</b> toward the 50S ribosomal subunit, with a binding free energy of −9.63 kcal/mol. Taken together, it could be deduced that compound <b>14</b> was a promising candidate for treating MRSA infections.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, Synthesis, Biological Evaluation, and Molecular Docking Studies of Pleuromutilin Derivatives Containing Thiazole\",\"authors\":\"Ke Li, Chao Lin, Yu-Han Hu, Jun Wang, Zhen Jin, Zhen-Ling Zeng* and You-Zhi Tang*, \",\"doi\":\"10.1021/acsinfecdis.3c00718\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >In this study, we designed and synthesized a series of pleuromutilin derivatives containing thiazole. The <i>in vitro</i> antimicrobial efficacy of these synthesized compounds was examined by using four strains. Compared with tiamulin (MIC = 0.25 μg/mL), compound <b>14</b> exhibited potency in inhibiting MRSA growth (MIC = 0.0625 μg/mL) in these derivatives. Meanwhile, the time-killing kinetics further demonstrated that compound <b>14</b> could efficiently inhibit the MRSA growth. After exposure at 4 × MIC, the postantibiotic effect (PAE) of compound <b>14</b> was 1.29 h. Additionally, in thigh-infected mice, compound <b>14</b> exhibited a more potent antibacterial efficacy (−1.78 ± 0.28 log<sub>10</sub> CFU/g) in reducing MRSA load compared to tiamulin (−1.21 ± 0.23 log<sub>10</sub> CFU/g). Moreover, the MTT assay on RAW 264.7 cells demonstrated that compound <b>14</b> (8 μg/mL) had no significant cytotoxicity. Docking studies indicated the strong affinity of compound <b>14</b> toward the 50S ribosomal subunit, with a binding free energy of −9.63 kcal/mol. Taken together, it could be deduced that compound <b>14</b> was a promising candidate for treating MRSA infections.</p>\",\"PeriodicalId\":17,\"journal\":{\"name\":\"ACS Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsinfecdis.3c00718\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.3c00718","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Design, Synthesis, Biological Evaluation, and Molecular Docking Studies of Pleuromutilin Derivatives Containing Thiazole
In this study, we designed and synthesized a series of pleuromutilin derivatives containing thiazole. The in vitro antimicrobial efficacy of these synthesized compounds was examined by using four strains. Compared with tiamulin (MIC = 0.25 μg/mL), compound 14 exhibited potency in inhibiting MRSA growth (MIC = 0.0625 μg/mL) in these derivatives. Meanwhile, the time-killing kinetics further demonstrated that compound 14 could efficiently inhibit the MRSA growth. After exposure at 4 × MIC, the postantibiotic effect (PAE) of compound 14 was 1.29 h. Additionally, in thigh-infected mice, compound 14 exhibited a more potent antibacterial efficacy (−1.78 ± 0.28 log10 CFU/g) in reducing MRSA load compared to tiamulin (−1.21 ± 0.23 log10 CFU/g). Moreover, the MTT assay on RAW 264.7 cells demonstrated that compound 14 (8 μg/mL) had no significant cytotoxicity. Docking studies indicated the strong affinity of compound 14 toward the 50S ribosomal subunit, with a binding free energy of −9.63 kcal/mol. Taken together, it could be deduced that compound 14 was a promising candidate for treating MRSA infections.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.